Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-cash Items (2020 - 2025)

Historic Non-cash Items for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $106.8 million.

  • Janux Therapeutics' Non-cash Items rose 176762.72% to $106.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.8 million, marking a year-over-year increase of 176762.72%. This contributed to the annual value of $361.6 million for FY2024, which is 681896.23% up from last year.
  • Janux Therapeutics' Non-cash Items amounted to $106.8 million in Q3 2025, which was up 176762.72% from $6.5 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Non-cash Items peaked at $361.6 million during Q4 2024, and registered a low of $5.1 million during Q2 2021.
  • Its 5-year average for Non-cash Items is $69.3 million, with a median of $27.6 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Janux Therapeutics' Non-cash Items was 224062.22% (2025), while the steepest drop was 9772.19% (2025).
  • Quarter analysis of 5 years shows Janux Therapeutics' Non-cash Items stood at $63.0 million in 2021, then plummeted by 52.65% to $29.8 million in 2022, then crashed by 43.86% to $16.7 million in 2023, then soared by 2060.97% to $361.6 million in 2024, then tumbled by 70.45% to $106.8 million in 2025.
  • Its Non-cash Items was $106.8 million in Q3 2025, compared to $6.5 million in Q2 2025 and $131.2 million in Q1 2025.